Results 141 to 150 of about 105,569 (311)

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Single-cell analysis identifies the CNP/GC-B/cGMP axis as marker and regulator of modulated VSMCs in atherosclerosis

Nature Communications
A balanced activity of cGMP signaling contributes to the maintenance of cardiovascular homeostasis. Vascular smooth muscle cells (VSMCs) can generate cGMP via three ligand-activated guanylyl cyclases, the NO-sensitive guanylyl cyclase, the atrial ...
Moritz Lehners, Hannes Schmidt, Maria T. K. Zaldivia, Daniel Stehle, Michael Krämer, Andreas Peter, Julia Adler, Robert Lukowski, Susanne Feil, Robert Feil   +9 more
doaj   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Detection of C-Type natriuretic peptide compared with brain and atrial natriuretic peptide transcripts in human heart by the polymerase chain reaction [PDF]

, 1993
Gerbes, Alexander L., Nemer, M.
core   +1 more source

A biomarker guided approach in heart failure [PDF]

, 2014
Heart failure is one of the commonest diagnoses presenting to physicians in the community or hospital care. Symptoms are often subjective, with clinicians having to rely on clinical assessment and radiological imaging to manage these patients.
Abela, Mark
core  

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

C‐type natriuretic peptide promotes human granulosa cell growth and estradiol production: Implications for early follicle development

Reproductive Medicine and Biology
Purpose To investigate the effects of C‐type natriuretic peptide (CNP) on human granulosa cell growth and elucidate its regulatory mechanisms. Methods A human non‐luteinizing granulosa cell line (HGrC) developed from small antral follicles was used to ...
Yorino Sato, Kazuhiro Kawamura
doaj   +1 more source

Processing and clearance of atrial natriuretic factor [PDF]

, 1991
Gerbes, Alexander L., Henriksen, Jens H., Vollmar, Angelika M.   +2 more
core   +1 more source